Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corvus Pharma Com (NQ: CRVS )

0.6801 -0.0248 (-3.52%)
Streaming Delayed Price Updated: 3:54 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 34,457
Open 0.7000
Bid (Size) 0.6402 (13)
Ask (Size) 0.7400 (16)
Prev. Close 0.7049
Today's Range 0.6800 - 0.7000
52wk Range 0.6100 - 2.110
Shares Outstanding 46,553,511
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via Globe NewsWire
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad... 
From Corvus Pharmaceuticals, Inc.
Via Globe NewsWire

Performance

YTD
-21.58%
-21.58%
1 Month
-11.23%
-11.23%
3 Month
-17.56%
-17.56%
6 Month
-12.81%
-12.81%
1 Year
-59.76%
-59.76%

More News

Read More
Corvus Pharma's HIV Candidate Shows Potential To Prevent Virus Re-Emergence
Via Benzinga
Earnings Scheduled For March 10, 2022
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal
From Corvus Pharmaceuticals, Inc.
Via Globe NewsWire
$1 Million Bet On BioCardia? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
4 Penny Stocks Insiders Are Buying: Getaround, Corvus Pharmaceuticals And More
Via Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
From Corvus Pharmaceuticals, Inc.
Via Globe NewsWire
Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
From Corvus Pharmaceuticals, Inc.
Via Globe NewsWire
James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology
From Corvus Pharmaceuticals, Inc.
Via Globe NewsWire
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
From Corvus Pharmaceuticals, Inc.
Via Globe NewsWire
Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
From Corvus Pharmaceuticals, Inc.
Via Globe NewsWire
Earnings Preview For Corvus Pharmaceuticals
Via Benzinga
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022
From Corvus Pharmaceuticals, Inc.
Via Globe NewsWire
Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer
From Corvus Pharmaceuticals, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2022
Via Benzinga
10 Best Stocks to Buy Now According to Jeffrey Diehl’s Adams Street Partners
Via Talk Markets
Corvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck Cancer
Via Benzinga
Corvus Pharmaceuticals: Q2 Earnings Insights
Via Benzinga
Recap: Corvus Pharmaceuticals Q4 Earnings
Via Benzinga
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
Via Benzinga
Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.